The ETERNAL project held a successful kick-off meeting in Valencia, Spain, on 27th and 28th September.
This new four-year EC Horizon Europe project will contribute to sustainable development of pharmaceutical manufacture, use and disposal. The ETERNAL consortium represents a team of sixteen parties bringing together knowledge and perspectives from the EU pharmaceuticals manufacturing value-chain, world-leading academics, specialist research centres and innovative SME.
AIMPLAS, Plastics Technology Centre, coordinates a new collaborative project to boost reduction of the environmental impact of pharmaceutical products through their entire life cycle. Funded under the Horizon Europe programme, the ETERNAL project held a successful kick-off meeting in Valencia, Spain on 27th and 28th September.
ETERNAL will contribute to the broad challenge of maintaining ongoing access to safe, high quality and effective pharmaceutical treatments for citizens and animals whilst ensuring sustainable supply chains and consumption patterns and avoiding undue impacts of pharmaceutical residues on the environment.
This new four-year EC Horizon Europe Research and Innovation Action (with GA number 101057668) will contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, usage, and disposal, assessing the environmental risks of not only active pharmaceutical ingredients and residues or metabolites, but other chemicals and by-products of the production process. In other words, safe and sustainable pharmaceutical lifecycles by design.
This sort of approach is essential to fully consider the types of green manufacturing currently under consideration by the pharmaceutical industry, something reflected in the range and scope of case studies that will be undertaken within the project. Specific application of the risk and life cycle assessment approaches being developed in the project to six ETERNAL case studies is a key element of the project’s workplan and will provide industry and policymakers with key examples of how whole life cycle assessment may be used to evaluate the changes in environmental impacts expected due to the introduction of green manufacturing processes.
Roadmap of technological innovations and consumer awareness campaigns
To meet this ambition the ETERNAL partners will advance a roadmap of relevant technological innovations – in biocatalysis, carcinogenic impurity capture, substitution of nonrecycled solvents, appropriate treatment of recycled solvents, membrane technology, continuous manufacturing processing and digitalization – towards green production methods and one-step disposal where drugs are fully metabolized in the body and break down immediately and harmlessly in the environment.
The project partners will also be working proactively with other specialist researchers using holistic approaches to increase understanding of the environmental impact and toxicity of pharmaceuticals among industry, the research community, and regulators to inform pharmaceutical strategies and policies based on scientific evidence.
Finally, ETERNAL will seek to create opportunities to catalyze behavioural change by piloting campaigns to inform consumers and patients about safe disposal methods for unused or expired medicines and promote the prescription of sustainable drug options among healthcare practitioners.
The ETERNAL consortium represents a powerful team of sixteen parties bringing together knowledge and perspectives from the EU pharmaceuticals manufacturing value-chain, world-leading academics, specialist research centres and innovative SME.
LinkedIn: https://www.linkedin.com/company/aimplas/ | Twitter: @aimplas | http://www.facebook.com/aimplas